Clinical trial
Dapagliflozin in Patients With Critical Illness: A Randomized Controlled Trial
NCT05558098 is registered in ClinicalTrials.gov with Hospital Israelita Albert Einstein as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dapagliflozin in Patients With Critical Illness: A Randomized Controlled Trial
- Lead sponsor
- Hospital Israelita Albert Einstein
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 1, 2022
- Completion date
- October 20, 2023
- Enrollment
- 507 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.